跳到内容

重型β地中海贫血(儿科)

药物诱导胎儿血红蛋白合成

羟基脲治疗

Efficacy of hydroxyurea in providing transfusion independence in β-thalassemia. (打开新窗口)

Ansari SH, Shamsi TS, Ashraf M, Perveen K, Farzana T, Bohray M, Erum S, Mehboob T.

来源‎: J Pediatr Hematol Oncol 2011;33(5):339-43.

检索‎: PubMed 21602718

DOI码‎: 10.1097/MPH.0b013e31821b0770

https://www.ncbi.nlm.nih.gov/pubmed/21602718 (打开新窗口)

Gγ-Xmn I polymorphism: a significant determinant of β-thalassemia treatment without blood transfusion. (打开新窗口)

Ansari SH, Shamsi TS, Munzir S, Khan MT, Erum S, Perveen K, Farzana T, Ashraf M, Mehboob T, Moinuddin M.

来源‎: J Pediatr Hematol Oncol 2013;35(4):e153-6.

检索‎: PubMed 23389500

DOI码‎: 10.1097/MPH.0b013e31827e8662

https://www.ncbi.nlm.nih.gov/pubmed/23389500 (打开新窗口)

Efficacy of hydroxyurea (HU) in reduction of pack red cell (PRC) transfusion requirement among children having beta-thalassemia major: Karachi HU trial (KHUT). (打开新窗口)

Ansari SH, Shamsi TS, Siddiqui FJ, Irfan M, Perveen K, Farzana T, Panjwani VK, Yousuf A, Mehboob T.

来源‎: J Pediatr Hematol Oncol 2007;29(11):743-6.

检索‎: PubMed 17984691

DOI码‎: 10.1097/MPH.0b013e318157fd75

https://www.ncbi.nlm.nih.gov/pubmed/17984691 (打开新窗口)

Hydroxyurea can eliminate transfusion requirements in children with severe beta-thalassemia. (打开新窗口)

Bradai M, Abad MT, Pissard S, Lamraoui F, Skopinski L, de Montalembert M.

来源‎: Blood 2003;102(4):1529-30.

检索‎: PubMed 12702505

DOI码‎: 10.1182/blood-2003-01-0117

https://www.ncbi.nlm.nih.gov/pubmed/12702505 (打开新窗口)

Decreased transfusion needs associated with hydroxyurea therapy in Algerian patients with thalassemia major or intermedia. (打开新窗口)

Bradai M, Pissard S, Abad MT, Dechartres A, Ribeil JA, Landais P, de Montalembert M.

来源‎: Transfusion 2007;47(10):1830-6.

检索‎: PubMed 17880608

DOI码‎: 10.1111/j.1537-2995.2007.01399.x

https://www.ncbi.nlm.nih.gov/pubmed/17880608 (打开新窗口)

Genotype-phenotype relationship of patients with β-thalassemia taking hydroxyurea: a 13-year experience in Iran. (打开新窗口)

Karimi M, Haghpanah S, Farhadi A, Yavarian M.

来源‎: Int J Hematol 2012;95(1):51-6.

检索‎: PubMed 22180324

DOI码‎: 10.1007/s12185-011-0985-6

https://www.ncbi.nlm.nih.gov/pubmed/22180324 (打开新窗口)

A randomised double-blind placebo-controlled clinical trial of oral hydroxyurea for transfusion-dependent β-thalassaemia. (打开新窗口)

Yasara N, Wickramarathne N, Mettananda C, Silva I, Hameed N, Attanayaka K, Rodrigo R, Wickramasinghe N, Perera L, Manamperi A, Premawardhena A, Mettananda S

来源‎: Sci Rep. 2022;12(1):2752.

检索‎: PubMed 35177777

DOI码‎: 10.1038/s41598-022-06774-8

https://pubmed.ncbi.nlm.nih.gov/35177777/ (打开新窗口)

Response to hydroxyurea treatment in Iranian transfusion-dependent beta-thalassemia patients. (打开新窗口)

Yavarian M, Karimi M, Bakker E, Harteveld CL, Giordano PC.

来源‎: Haematologica 2004;89(10):1172-8.

检索‎: PubMed 15477200

https://www.ncbi.nlm.nih.gov/pubmed/15477200 (打开新窗口)

Hydroxyurea therapy in 49 patients with major beta-thalassemia. (打开新窗口)

Zamani F, Shakeri R, Eslami SM, Razavi SM, Basi A.

来源‎: Arch Iran Med 2009;12(3):295-7.

检索‎: PubMed 19400608

https://www.ncbi.nlm.nih.gov/pubmed/19400608 (打开新窗口)

重组人促红细胞生成素(单用或跟其他药物联合使用)

Use of hydroxyurea and recombinant erythropoietin in management of homozygous ß⁰ thalassemia. (打开新窗口)

Kohli-Kumar M, Marandi H, Keller MA, Guertin K, Hvizdala E.

来源‎: J Pediatr Hematol Oncol 2002;24(9):777-8.

检索‎: PubMed 12468925

https://www.ncbi.nlm.nih.gov/pubmed/12468925 (打开新窗口)

其他制剂

Fetal globin gene inducers: novel agents and new potential. (打开新窗口)

Perrine SP, Castaneda SA, Chui DH, Faller DV, Berenson RJ, Siritanaratku N, Fucharoen S.

来源‎: Ann N Y Acad Sci 2010;1202:158-64.

检索‎: PubMed 20712788

DOI码‎: 10.1111/j.1749-6632.2010.05593.x

https://www.ncbi.nlm.nih.gov/pubmed/20712788 (打开新窗口)